SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB

Zhou,Ming; Wang,Aman; Yin,Baosheng; Wu,Dan; Han,Shiliang; Zhang,Wenpeng; Liu,Jiwei; Sun,Kang

doi:10.3892/or.2018.6822

SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB

Authors:
- Ming Zhou
- Aman Wang
- Baosheng Yin
- Dan Wu
- Shiliang Han
- Wenpeng Zhang
- Jiwei Liu
- Kang Sun
View Affiliations

Affiliations: Department of Orthopaedics, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Orthopaedics, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Burns and Plastic Surgery, Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China, Department of Orthopaedics, Central Hospital of Zibo, Zibo, Shandong 255036, P.R. China
Published online on: October 24, 2018 https://doi.org/10.3892/or.2018.6822
Pages: 579-589

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most frequent primary bone tumor. Staphylococcal nuclease domain‑containing 1 (SND1) is a multifunctional protein that plays important roles in tumor development and progression. Overexpression of SND1 has been found in several malignancies, however, its expression and function in osteosarcoma is largely unknown. In the present study, we firstly examined the expression of SND1 in 12 pairs of osteosarcoma and healthy bones by immunoblotting and real time‑PCR. The results revealed that osteosarcoma tissues expressed significantly high SND1 mRNA and protein expression compared to normal bone tissues. Next, we stably overexpressed SND1 ORF in MG‑63 cells and further defined the biological function of SND1 in osteosarcoma by flow cytometry, cell proliferation and in vivo assays. We found that SND1 overexpression significantly promoted cell proliferation and tumor growth in vitro and in vivo. Furthermore, the non‑targeted metabolic profiling, ELISA and luciferase reporter assays were performed on stable overexpressing cells and blood samples to elucidate the underlying mechanisms of SND1‑mediated oncogenic features. The results revealed that SND1 increased the production of arachidonic acid PGE2. The serum PGE2 expression level had a significant positive association with the SND1 mRNA expression level in osteosarcoma tissues. The SND1 overexpression‑stimulated cell proliferation was enhanced by exogenous addition of PGE2. Additionally, we found that SND1 upregulated PGE2 expression through the NF‑κB/cyclooxygenase‑2 (COX‑2) pathway. In summary, our findings revealed the mechanisms of SND1 involvement in osteosarcoma tumor development, and support the targeting of SND1 as a new anti‑tumor strategy for patients with osteosarcoma. In addition, SND1 may act as a potential biomarker of the therapeutic strategies utilizing COX‑2 inhibitors.

View Figures

View References

1	Hingorani P, Janeway K, Crompton BD, Kadoch C, Mackall CL, Khan J, Shern JF, Schiffman J, Mirabello L, Savage SA, et al: Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 209:182–194. 2016. View Article : Google Scholar : PubMed/NCBI
2	Harrison DJ, Geller DS, Gill JD, Lewis VO and Gorlick R: Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018. View Article : Google Scholar : PubMed/NCBI
3	Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
4	Pang LY, Hurst EA and Argyle DJ: Cyclooxygenase-2: A role in cancer stem cell survival and repopulation of cancer cells during therapy. Stem Cells Int. 2016:20487312016. View Article : Google Scholar : PubMed/NCBI
5	Xu L, Stevens J, Hilton MB, Seaman S, Conrads TP, Veenstra TD, Logsdon D, Morris H, Swing DA, Patel NL, et al: COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 6:242ra842014. View Article : Google Scholar : PubMed/NCBI
6	Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J and Ochoa AC: Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 202:931–939. 2005. View Article : Google Scholar : PubMed/NCBI
7	Cha YI and DuBois RN: NSAI Ds and cancer prevention: Targets downstream of COX-2. Annu Rev Med. 58:239–252. 2007. View Article : Google Scholar : PubMed/NCBI
8	Naruse T, Nishida Y, Hosono K and Ishiguro N: Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 27:584–592. 2006. View Article : Google Scholar : PubMed/NCBI
9	Qu L and Liu B: Cyclooxygeanse-2 promotes metastasis in osteosarcoma. Cancer Cell Int. 15:692015. View Article : Google Scholar : PubMed/NCBI
10	Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, Hawkins DS, Munsell MF and Kleinerman ES: COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 30:507–512. 2008. View Article : Google Scholar : PubMed/NCBI
11	Gutierrez-Beltran E, Denisenko TV, Zhivotovsky B and Bozhkov PV: Tudor staphylococcal nuclease: Biochemistry and functions. Cell Death Differ. 23:1739–1748. 2016. View Article : Google Scholar : PubMed/NCBI
12	Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, Pannell L, Fisher PB and Sarkar D: Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology. 53:1538–1548. 2011. View Article : Google Scholar : PubMed/NCBI
13	Jariwala N, Rajasekaran D, Srivastava J, Gredler R, Akiel MA, Robertson CL, Emdad L, Fisher PB and Sarkar D: Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review). Int J Oncol. 46:465–473. 2015. View Article : Google Scholar : PubMed/NCBI
14	Pandey MK, Gupta SC, Nabavizadeh A and Aggarwal BB: Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. Semin Cancer Biol. 46:158–181. 2017. View Article : Google Scholar : PubMed/NCBI
15	Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
16	Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS Jr, Fisher PB and Sarkar D: Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem. 287:13952–13958. 2012. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Piao H, Yuan Y, Wang M, Sun Y, Liang H and Ma L: α-catenin acts as a tumor suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-κB signaling. Nat Cell Biol. 16:245–254. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, Xu L, Li X, Liu H, Yin P, et al: Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 7:91102017. View Article : Google Scholar : PubMed/NCBI
20	Lin YH, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL and Lee DF: Osteosarcoma: Molecular pathogenesis and iPSC modeling. Trends Mol Med. 23:737–755. 2017. View Article : Google Scholar : PubMed/NCBI
21	Taran SJ, Taran R and Malipatil NB: Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol. 38:33–43. 2017. View Article : Google Scholar : PubMed/NCBI
22	Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura T and Nakagama H: SN D1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res. 67:9568–9576. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wang N, Du X, Zang L, Song N, Yang T, Dong R, Wu T, He X and Lu J: Prognostic impact of Metadherin-SND1 interaction in colon cancer. Mol Biol Rep. 39:10497–10504. 2012. View Article : Google Scholar : PubMed/NCBI
24	Xing A, Pan L and Gao J: p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer. Thorac Cancer. 9:152–158. 2018. View Article : Google Scholar : PubMed/NCBI
25	Jin SJ, Lee A, Li J, Liyanage H, Yang Y, Guo L, Asmann YW, Li PW, Erickson-Johnson M, Sakai Y, et al: Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep. 5:97552015. View Article : Google Scholar : PubMed/NCBI
26	Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, Miki K, Miki J, Sasaki H, Hayashi N and Egawa S: Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. Am J Pathol. 174:2044–2050. 2009. View Article : Google Scholar : PubMed/NCBI
27	Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N and Lim YP: Novel breast cancer metastasis-associated proteins. J Proteome Res. 8:583–594. 2009. View Article : Google Scholar : PubMed/NCBI
28	Jariwala N, Rajasekaran D, Mendoza RG, Shen XN, Siddiq A, Akiel MA, Robertson CL, Subler MA, Windle JJ, Fisher PB, et al: Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. Cancer Res. 77:3306–3316. 2017. View Article : Google Scholar : PubMed/NCBI
29	Bilbao-Aldaiturriaga N, Gutierrez-Camino A, Martin-Guerrero I, Pombar-Gomez M, Zalacain-Diez M, Patiño-Garcia A, Lopez-Lopez E and Garcia-Orad A: Polymorphisms in miRNA processing genes and their role in osteosarcoma risk. Pediatr Blood Cancer. 62:766–769. 2015. View Article : Google Scholar : PubMed/NCBI
30	Su C, Zhang C, Tecle A, Fu X, He J, Song J, Zhang W, Sun X, Ren Y, Silvennoinen O, et al: Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G₁/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation. J Biol Chem. 290:7208–7220. 2015. View Article : Google Scholar : PubMed/NCBI
31	Netea-Maier RT, Smit Jwa and Netea MG: Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. Cancer Lett. 413:102–109. 2018. View Article : Google Scholar : PubMed/NCBI
32	Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, Dowluru KS, Chintala R and Duddukuri GR: Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol 40-. 41:48–81. 2016. View Article : Google Scholar
33	Zhou Z, Ibekwe E and Chornenkyy Y: Metabolic alterations in cancer cells and the emerging role of oncometabolites as drivers of neoplastic change. Antioxidants. 7:E162018. View Article : Google Scholar : PubMed/NCBI
34	Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M and Dubinett SM: Prostaglandin E₂ activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 65:6275–6281. 2005. View Article : Google Scholar : PubMed/NCBI
35	Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E₂ promotes colon cancer cell growth through a G_s-axin-β-catenin signaling axis. Science. 310:1504–1510. 2005. View Article : Google Scholar : PubMed/NCBI
36	Consalvi S, Biava M and Poce G: COX inhibitors: A patent review (2011–2014). Expert Opin Ther Pat. 25:1357–1371. 2015. View Article : Google Scholar : PubMed/NCBI